Skip to main content
Journal cover image

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.

Publication ,  Journal Article
Hohnloser, SH; Hijazi, Z; Thomas, L; Alexander, JH; Amerena, J; Hanna, M; Keltai, M; Lanas, F; Lopes, RD; Lopez-Sendon, J; Granger, CB; Wallentin, L
Published in: Eur Heart J
November 2012

AIMS: Atrial fibrillation (AF) is common among patients with impaired renal function. Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial. We evaluated these outcomes in relation to renal function. METHODS AND RESULTS: Baseline glomerular filtration rate (GFR) was estimated using the Cockcroft-Gault and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations as well as cystatin C measurements. According to baseline Cockcroft-Gault, there were 7518 patients (42%) with an estimated GFR (eGFR) of >80 mL/min, 7587 (42%) between >50 and 80 mL/min, and 3017 (15%) with an eGFR of ≤50 mL/min. The rate of cardiovascular events and bleeding was higher at impaired renal function (≤80 mL/min). Apixaban was more effective than warfarin in preventing stroke or systemic embolism and reducing mortality irrespective of renal function. These results were consistent, regardless of methods for GFR estimation. Apixaban was associated with less major bleeding events across all ranges of eGFRs. The relative risk reduction in major bleeding was greater in patients with an eGFR of ≤50 mL/min using Cockcroft-Gault {hazard ratio (HR) 0.50 [95% confidence interval (CI) 0.38-0.66], interaction P = 0.005} or CKD-EPI equations [HR 0.48 (95% CI 0.37-0.64), interaction P = 0.003]. CONCLUSION: In patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding. When compared with warfarin, apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function. Patients with impaired renal function seemed to have the greatest reduction in major bleeding with apixaban.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Heart J

DOI

EISSN

1522-9645

Publication Date

November 2012

Volume

33

Issue

22

Start / End Page

2821 / 2830

Location

England

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Stroke
  • Risk Factors
  • Renal Insufficiency, Chronic
  • Pyridones
  • Pyrazoles
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hohnloser, S. H., Hijazi, Z., Thomas, L., Alexander, J. H., Amerena, J., Hanna, M., … Wallentin, L. (2012). Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J, 33(22), 2821–2830. https://doi.org/10.1093/eurheartj/ehs274
Hohnloser, Stefan H., Ziad Hijazi, Laine Thomas, John H. Alexander, John Amerena, Michael Hanna, Matyas Keltai, et al. “Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.Eur Heart J 33, no. 22 (November 2012): 2821–30. https://doi.org/10.1093/eurheartj/ehs274.
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33(22):2821–30.
Hohnloser, Stefan H., et al. “Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.Eur Heart J, vol. 33, no. 22, Nov. 2012, pp. 2821–30. Pubmed, doi:10.1093/eurheartj/ehs274.
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33(22):2821–2830.
Journal cover image

Published In

Eur Heart J

DOI

EISSN

1522-9645

Publication Date

November 2012

Volume

33

Issue

22

Start / End Page

2821 / 2830

Location

England

Related Subject Headings

  • Warfarin
  • Treatment Outcome
  • Stroke
  • Risk Factors
  • Renal Insufficiency, Chronic
  • Pyridones
  • Pyrazoles
  • Middle Aged
  • Male
  • Humans